The precision medicine research spinout from Cold Spring Habor Laboratory has secured seed capital in a round led by Dynamk Capital.
Envisagenics, a US-based precision medicine research spinout from Cold Spring Harbor Laboratory, secured $2.25m in a seed round today led by VC fund Dynamk Capital.
Dynamk committed $500,000 to the round, investing alongside a group of unnamed private investors.
Founded in 2014, Envisagenics has developed a drug discovery platform that aims to provide researchers with an easier way to identify disease biomarkers and targets.
The computer simulation service uses machine learning to analyse the genetic script for ribonucleic acid (RNA)…
